-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
IDEAYA Biosciences (NASDAQ:IDYA) Given New $32.00 Price Target at Guggenheim
IDEAYA Biosciences (NASDAQ:IDYA) Given New $32.00 Price Target at Guggenheim
IDEAYA Biosciences (NASDAQ:IDYA – Get Rating) had its price objective boosted by Guggenheim from $20.00 to $32.00 in a research note released on Tuesday, The Fly reports. The brokerage currently has a buy rating on the stock.
Several other equities research analysts have also issued reports on IDYA. Stifel Nicolaus lowered IDEAYA Biosciences from a buy rating to a hold rating and decreased their target price for the company from $16.00 to $13.00 in a research report on Monday, August 15th. Roth Capital raised their target price on IDEAYA Biosciences from $42.00 to $46.00 in a research report on Tuesday, May 17th. Oppenheimer raised their target price on IDEAYA Biosciences to $22.00 in a research report on Tuesday, September 6th. Finally, Robert W. Baird decreased their target price on IDEAYA Biosciences from $26.00 to $18.00 and set an outperform rating for the company in a research report on Tuesday, August 16th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, IDEAYA Biosciences has a consensus rating of Moderate Buy and an average target price of $27.50.
Get IDEAYA Biosciences alerts:IDEAYA Biosciences Trading Down 5.1 %
NASDAQ IDYA opened at $11.16 on Tuesday. The firm has a market capitalization of $438.65 million, a P/E ratio of -6.53 and a beta of 1.51. The business has a fifty day simple moving average of $12.84 and a 200 day simple moving average of $12.01. IDEAYA Biosciences has a 12 month low of $8.14 and a 12 month high of $27.71.
IDEAYA Biosciences (NASDAQ:IDYA – Get Rating) last released its quarterly earnings results on Monday, August 15th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). IDEAYA Biosciences had a negative net margin of 225.95% and a negative return on equity of 22.38%. As a group, sell-side analysts predict that IDEAYA Biosciences will post -2.27 EPS for the current fiscal year.Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in IDYA. Nisa Investment Advisors LLC bought a new position in IDEAYA Biosciences in the 2nd quarter worth about $25,000. Point72 Hong Kong Ltd boosted its stake in IDEAYA Biosciences by 363.7% in the 1st quarter. Point72 Hong Kong Ltd now owns 3,376 shares of the company's stock worth $38,000 after purchasing an additional 2,648 shares during the period. Quantbot Technologies LP boosted its stake in IDEAYA Biosciences by 90.5% in the 1st quarter. Quantbot Technologies LP now owns 4,000 shares of the company's stock worth $44,000 after purchasing an additional 1,900 shares during the period. Amalgamated Bank bought a new position in IDEAYA Biosciences in the 1st quarter worth about $48,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in IDEAYA Biosciences by 12.7% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,416 shares of the company's stock worth $117,000 after purchasing an additional 1,171 shares during the period. Institutional investors own 93.25% of the company's stock.
IDEAYA Biosciences Company Profile
(Get Rating)
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.
See Also
- Get a free copy of the StockNews.com research report on IDEAYA Biosciences (IDYA)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- No One Told These 3 Stocks It's a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
- Is There a Cure for What is Ailing Teladoc Stock?
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
IDEAYA Biosciences (NASDAQ:IDYA – Get Rating) had its price objective boosted by Guggenheim from $20.00 to $32.00 in a research note released on Tuesday, The Fly reports. The brokerage currently has a buy rating on the stock.
据The Fly报道,在周二发布的一份研究报告中,古根海姆将IDEAYA生物科学公司(纳斯达克:IDYA-GET评级)的目标价从20.00美元上调至32.00美元。该经纪公司目前对该股的评级为买入。
Several other equities research analysts have also issued reports on IDYA. Stifel Nicolaus lowered IDEAYA Biosciences from a buy rating to a hold rating and decreased their target price for the company from $16.00 to $13.00 in a research report on Monday, August 15th. Roth Capital raised their target price on IDEAYA Biosciences from $42.00 to $46.00 in a research report on Tuesday, May 17th. Oppenheimer raised their target price on IDEAYA Biosciences to $22.00 in a research report on Tuesday, September 6th. Finally, Robert W. Baird decreased their target price on IDEAYA Biosciences from $26.00 to $18.00 and set an outperform rating for the company in a research report on Tuesday, August 16th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, IDEAYA Biosciences has a consensus rating of Moderate Buy and an average target price of $27.50.
其他几位股票研究分析师也发布了关于IDYA的报告。Stifel Nicolaus在8月15日周一的一份研究报告中将IDEAYA Biosciences的评级从买入下调至持有,并将该公司的目标价从16.00美元下调至13.00美元。Roth Capital在5月17日周二的一份研究报告中将IDEAYA Biosciences的目标价从42.00美元上调至46.00美元。奥本海默在9月6日(星期二)的一份研究报告中将他们对IDEAYA生物科学公司的目标价上调至22.00美元。最后,罗伯特·W·贝尔德在8月16日星期二的一份研究报告中将他们对IDEAYA生物科学公司的目标价从26.00美元下调至18.00美元,并为该公司设定了表现优于大盘的评级。一名投资分析师对该股的评级为持有,五名分析师对该公司的评级为买入。根据MarketBeat的数据,IDEAYA Biosciences的共识评级为中等买入,平均目标价为27.50美元。
IDEAYA Biosciences Trading Down 5.1 %
IDEAYA生物科学公司股价下跌5.1%
NASDAQ IDYA opened at $11.16 on Tuesday. The firm has a market capitalization of $438.65 million, a P/E ratio of -6.53 and a beta of 1.51. The business has a fifty day simple moving average of $12.84 and a 200 day simple moving average of $12.01. IDEAYA Biosciences has a 12 month low of $8.14 and a 12 month high of $27.71.
纳斯达克IDYA周二开盘报11.16美元。该公司的市值为4.3865亿美元,市盈率为-6.53,贝塔系数为1.51。该业务的50日简单移动均线为12.84美元,200日简单移动均线为12.01美元。IDEAYA Biosciences的12个月低点为8.14美元,12个月高位为27.71美元。
Institutional Inflows and Outflows
机构资金流入和流出
Several large investors have recently added to or reduced their stakes in IDYA. Nisa Investment Advisors LLC bought a new position in IDEAYA Biosciences in the 2nd quarter worth about $25,000. Point72 Hong Kong Ltd boosted its stake in IDEAYA Biosciences by 363.7% in the 1st quarter. Point72 Hong Kong Ltd now owns 3,376 shares of the company's stock worth $38,000 after purchasing an additional 2,648 shares during the period. Quantbot Technologies LP boosted its stake in IDEAYA Biosciences by 90.5% in the 1st quarter. Quantbot Technologies LP now owns 4,000 shares of the company's stock worth $44,000 after purchasing an additional 1,900 shares during the period. Amalgamated Bank bought a new position in IDEAYA Biosciences in the 1st quarter worth about $48,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in IDEAYA Biosciences by 12.7% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,416 shares of the company's stock worth $117,000 after purchasing an additional 1,171 shares during the period. Institutional investors own 93.25% of the company's stock.
几家大型投资者最近增持或减持了IDYA的股份。NISA Investment Advisors LLC在第二季度购买了IDEAYA Biosciences的新头寸,价值约25,000美元。Point72 Hong Kong Ltd在第一季度增持了IDEAYA Biosciences的股份363.7%。Point72 Hong Kong Ltd在此期间额外购买了2,648股,目前持有该公司3,376股股票,价值38,000美元。Quantbot Technologies LP在第一季度增持了IDEAYA Biosciences 90.5%的股份。在此期间,Quantbot Technologies LP又购买了1900股,现在拥有4000股该公司股票,价值4.4万美元。合并银行在第一季度购买了IDEAYA生物科学公司的一个新头寸,价值约48,000美元。最后,三菱UFJ国赛资产管理有限公司在第一季度将其在IDEAYA Biosciences的持股增加了12.7%。三菱UFJ国赛资产管理有限公司在此期间增购了1,171股后,现在持有10,416股该公司股票,价值11.7万美元。机构投资者持有该公司93.25%的股票。
IDEAYA Biosciences Company Profile
IDEAYA生物科学公司简介
(Get Rating)
(获取评级)
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.
IDEAYA生物科学公司是一家专注于合成致命性的精确医学肿瘤学公司,专注于为使用分子诊断技术选择的患者群体发现和开发靶向疗法。该公司的主要候选产品包括甲硫氨酸腺苷转移酶2a抑制剂IDE397和蛋白激酶C抑制剂IDE196。IDE397是一种蛋氨酸腺苷转移酶2a抑制剂,正处于甲硫腺苷磷酸化酶缺失的实体肿瘤患者的第一阶段临床试验中;IDE196是一种蛋白激酶C抑制剂,正处于针对具有GNAQ或GNA11基因突变的基因定义癌症的第一/第二阶段临床试验。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on IDEAYA Biosciences (IDYA)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- No One Told These 3 Stocks It's a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
- Is There a Cure for What is Ailing Teladoc Stock?
- 免费获取StockNews.com关于IDEAYA生物科学的研究报告(IDYA)
- 第四季度值得考虑的3家银行
- 股市:红海中的三座强国
- 没有人告诉这三只股票这是下跌的一周
- MarketBeat:回顾一周9/12-9/16
- 有什么办法可以治愈Teladoc股票的问题吗?
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
获得IDEAYA生物科学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对IDEAYA生物科学和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧